The world's first oral GLP-1RA, Novo Nordisk's Rybelsus®, is fully launched in China

Wallstreetcn
2025.01.11 10:09

On January 11, 2025, Novo Nordisk announced the full launch of its innovative drug, Novo Nordisk® (semaglutide tablets), in China. As the first oral GLP-1 receptor agonist, Novo Nordisk® breakthroughly combines SNAC technology to achieve significant benefits in glycemic control, weight loss, blood pressure reduction, and lipid regulation. The once-daily oral administration will enhance patient compliance, opening a new chapter in the treatment of type 2 diabetes, assisting in achieving quality blood sugar standards and comprehensive metabolic management, bringing new hope to China's 140 million diabetes patients

Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.